1 / 7

Weesziekten en weesgeneesmiddelen

Weesziekten en weesgeneesmiddelen. Weesziekte of zeldzame ziekte : Prevalentie < 1/2000 Bv : mucoviscidose 1/5000, hemofilie 1 /10.000 Maar: ziekte van Crohn 6/2000, ijzerstapelingsziekte ( hemochromatose ) 1/200

leo-larson
Download Presentation

Weesziekten en weesgeneesmiddelen

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Weesziekten en weesgeneesmiddelen • Weesziekte of zeldzameziekte: Prevalentie < 1/2000 Bv: mucoviscidose 1/5000, hemofilie 1/10.000 Maar: ziekte van Crohn 6/2000, ijzerstapelingsziekte (hemochromatose) 1/200 • Weesgeneesmiddel: eengeneesmiddeldatenkel (vooral?) dientomeenweesziektetebehandelen

  2. Orphan drug regulation United States: Orphan Drug Act (1983) Europe (2000)

  3. Incentives • Market exclusivity for a period of 10 years • protects against a ‘similar’ drug being authorized in the EU for the same therapeutic indication • Protocol and scientific assistance • wrt clinical and non-clinical aspects of drug development • Access to the centralized registration procedure • Access to EU-funded research • Incentives undertaken on a national level + Fee reductions • such as full or partial EMA fee waivers

  4. Criteria for orphan designation (Art. 3) A medicinal product intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition 1° that affects not more that 5 in 10 000 people in the Community (prevalence criterion) OR 2° that without incentives it would be unlikely to generate sufficient return the justify the investment (return on investment criterion) There is no satisfactory method of diagnosis, prevention or treatment of the condition. OR If such a method does exist, that the medicinal product will be of significant benefit to those affected. AND

  5. Current status (Westermark, 2011) Orphan designations

  6. Current status Market authorizations 60 authorized orphan drugs (October 2011) (KCE, 2010)

More Related